Medesis Pharma S.A.
ALMDP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010844464
- LEI:
- 969500C15M96P00UR648
- Country:
- France
- Address:
- AVENUE DU GOLF, 34670 BAILLARGUES
- Website:
- https://www.medesispharma.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Medesis Pharma S.A. is a clinical-stage biotechnology company developing treatments for serious diseases that currently lack effective therapies. The company's core technology is AONYS®, a proprietary drug delivery platform. AONYS® is a micro-emulsion for buccal (oral) administration that facilitates the intracellular delivery of various therapeutic molecules, including interfering RNAs, metal ions, and peptides. A key feature of the platform is its ability to cross the blood-brain barrier, enabling the development of treatments for central nervous system disorders. The technology is designed to transport active ingredients within HDL lipoproteins, making them invisible to the immune system. Medesis Pharma's development pipeline focuses on creating drug candidates for areas such as neurodegenerative diseases, oncology, and countermeasures for nuclear radiation exposure.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Medesis Pharma S.A..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-03-20 12:00 |
Legal Proceedings Report
MEDESIS PHARMA : OUVERTURE D'UNE PROCÉDURE DE LIQUIDATION JUDICIAIRE
|
French | 184.2 KB | |
| 2024-11-20 17:45 |
Earnings Release
MEDESIS PHARMA A FINALISÉ L’ÉTUDE CLINIQUE POUR LE TRAITEMENT DE LA MALADIE D’A…
|
French | 685.0 KB | |
| 2024-11-20 17:45 |
Regulatory News Service
MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'…
|
English | 614.2 KB | |
| 2024-11-14 18:00 |
Legal Proceedings Report
MEDESIS PHARMA : CONVERSION DE LA PROCÉDURE DE SAUVEGARDE EN REDRESSEMENT JUDIC…
|
French | 314.0 KB | |
| 2024-11-12 18:00 |
Quarterly Report
MEDESIS PHARMA : Rapport Financier Semestriel 2024
|
French | 2.5 MB | |
| 2024-11-12 18:00 |
Earnings Release
MEDESIS PHARMA : Activités & résultats du 1er semestre 2024
|
French | 1.1 MB | |
| 2024-10-08 08:00 |
Report Publication Announcement
Participation de MEDESIS PHARMA au Congrès mondial pour les études cliniques s…
|
French | 487.6 KB | |
| 2024-10-08 08:00 |
Earnings Release
MEDESIS PHARMA to participate to the World Congress for Clinical Trials in Alz…
|
English | 461.5 KB | |
| 2024-09-20 08:00 |
Earnings Release
MEDESIS PHARMA : Résultats encourageants de la première phase de l’essai cliniq…
|
French | 236.8 KB | |
| 2024-09-04 17:45 |
Pre-Annual General Meeting Information
MEDESIS PHARMA : MISE À DISPOSITION DES DOCUMENTS PRÉPARATOIRES À L’ASSEMBLÉE G…
|
French | 274.7 KB | |
| 2024-07-15 08:00 |
Earnings Release
MEDESIS PHARMA : ACTIVITÉS & RÉSULTATS ANNUELS 2023
|
French | 828.9 KB | |
| 2024-07-15 08:00 |
Annual Report
MEDESIS PHARMA: 2023 FULL-YEAR BUSINESS AND EARNINGS
|
English | 737.2 KB | |
| 2024-06-03 18:00 |
Regulatory News Service
MEDESIS PHARMA : Obtention d’un financement pour poursuivre l'analyse des résul…
|
French | 498.8 KB | |
| 2024-03-19 18:01 |
Share Issue/Capital Change
Termination of the agreement between NICE and GREEN S.A. and Medesis Pharma
|
English | 264.7 KB | |
| 2024-03-19 18:01 |
Capital/Financing Update
Medesis Pharma : Résiliation du contrat avec la société NICE & GREEN S.A.
|
French | 302.0 KB |
Automate Your Workflow. Get a real-time feed of all Medesis Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Medesis Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-16 | N/A | Other | Sell | 1,000 | 1,170.00 EUR |
| 2024-01-18 | N/A | Other | Sell | 800 | 669.60 EUR |
| 2023-07-21 | N/A | Other | Sell | 1,000 | 1,400.00 EUR |
| 2023-07-04 | N/A | Other | Sell | 5,000 | 7,100.00 EUR |
| 2023-05-23 | N/A | Other | Sell | 3,140 | 6,908.00 EUR |
